Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q6GQQ9

UPID:
OTU7B_HUMAN

ALTERNATIVE NAMES:
Cellular zinc finger anti-NF-kappa-B protein; Zinc finger A20 domain-containing protein 1; Zinc finger protein Cezanne

ALTERNATIVE UPACC:
Q6GQQ9; B7Z643; D3DUZ8; Q5SZ60; Q8WWA7; Q9NQ53; Q9UFF4

BACKGROUND:
Known alternatively as Zinc finger A20 domain-containing protein 1, OTU domain-containing protein 7B is pivotal in immune regulation. It prevents over-activation of non-canonical NF-kappa-B by deubiquitinating TRAF3 and plays a role in T cell responses by acting on ZAP70. Its activity towards various polyubiquitin chains underscores its significance in cellular signaling.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of OTU domain-containing protein 7B offers a promising avenue for developing novel immunotherapies. Its critical role in immune regulation highlights its therapeutic potential in diseases involving immune dysregulation.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.